Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update

Gamgertamig poster accepted for presentation at the 2026 ASH1 Annual Meeting, featuring data from ongoing Phase 1b studies that suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune re…